Introduction
Usher syndrome (USH) is an autosomal, recessively inherited condition, which manifests as deafness, retinitis pigmentosa (RP) and, in some cases, vestibular dysfunction. The prevalence has been estimated from 1/ 6000 to 1/ 25000 (1) . There are three clinical subtypes classified by the severity and onset of hearing loss and retinitis pigmentosa. USH1 is the most severe form, characterized by congenital severe to profound deafness and prepubertal onset of RP. Furthermore, children also have vestibular areflexia and absent vestibular function. Seven genes associated with this form have been identified: MYO7A, CDH23, PCDH15, USH1C, USH1G, CIB2 and ESPN (2) (3) (4) (5) . USH2 is a more frequent type, Next-generation sequencing reveals three novel variants in Polish patients with Usher syndrome Nowe mutacje wykryte u pacjentów z zespołem Ushera przy użyciu techniki sekwencjonowania następnej generacji ISSN 0023-2157 Index 362646
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Methods
Clinical studies Seven patients from unrelated Polish families (one patient from each family) manifesting clinical features of Usher syndrome participated in this study. Their parents did not show any symptoms of USH syndrome or other ocular symptoms. The patients received genetic counseling with detailed medical data analysis. Ocular assessment including central visual acuity measurement, fundus examination, electroretinography (ERG) and optical coherence tomography (OCT) was performed. Pure tone audiometry (PTA) was performed in all patients. One patient (p5) underwent neuro-imaging with high-resolution MRI to exclude brain and inner ear malformations. All patients agreed to participate in the study and to use their anonymized data in the publication. This study conforms to the Helsinki declaration and was approved by the Poznan University of Medical Sciences Institutional Review Board. Informed consent was obtained from them prior to molecular testing.
Molecular genetic analysis
Blood samples were collected and genomic DNA was extracted from peripheral blood leukocytes using the salting-out method. NGS with Illumina NextSeq on the diagnostic panel for Usher syndrome (Asper Biotech, Tartu, Estonia) was performed in all patients . A panel of 20 genes including ABHD12, CDH23, CIB2,  CLRN1, COL4A6, DFNB31, DSPP (excluding exon 5), GIPC3,  GPR98, HARS, KARS, LHFPL5, LOXHD1, MYO7A, PCDH15, PDZD7 , TNC, USH2A, USH1C and USH1G was analyzed. The read depth of the tested genes included in the panel was between 70-120x. The sequences were verified by comparing them to the human reference sequence of the GPR98 gene (NM_032119.4), MYO7A (NM_001127180.1) and USH2A (NM_206933.2) genes. The identified sequences variants were referred to the Human Gene Mutation Database (HGMD), the Exome Variant Server (NHLBI Exome Sequencing Project ESP), the 1000 Genomes Project database (1000 Genomes Project Consortium 2012) and ExAC Browser Beta (Exome Aggregation Consortium 2015). The in silico analyses using SIFT, PolyPhen-2 and MutationTaster 2 software were performed to predict the possible effect of the novel missense variants. The evolutionary conservation of nucleotide positions was analyzed by PhyloP and GERP ++ scores. To predict the impact of substitution between amino acids, the Grantham score was analyzed. Novel variants identified in this study were classified according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG) guidelines (13) . A control cohort of 100 healthy, ethnically matched individuals from the Genetics Department of Poznan University of Medical Sciences database, was used to verify novel variants identified in this study. Segregation analysis for the presence of altered alleles was performed in the families (families 1, 2, 3) with the novel potentially causative variants in GPR98, MYO7A and USH2A genes by Sanger sequencing of the appropriate exons (Fig. 1) .
Results
The diagnosis was based on clinical, audiometric and ophthalmic data. Patients were identified as having USH1 and USH2 type according to the clinical features. The audiometric test demonstrated a congenital, bilateral hearing loss ranging from moderate to severe in the USH2 patients. In a USH1 patient (p2), deafness was defined as bilateral and profound, and was reported to be present in infancy. Parents of a p2 patient reported that the gait and balance problems were present from early childhood. All patients presented with typical signs and symptoms of RP, including night blindness, visual field narrowing, bone spicule-like pigmentation, retinal vessel attenuation and optic disc pallor. Furthermore, in three patients (p1, p5 and p6) cystoid macular edema (CME) was diagnosed. The clinical data has been shown in Table I . An example of typical ERG, OCT and audiometric findings (sourced from the patient p3) are presented in Figure 2 .
Molecular results
In our cohort of seven patients diagnosed with USH, mutations in a compound heterozygous state were identified in five patients (71.4%) while in two patients (p5 and p7) only one mutated allele was identified. Three novel variants were detected in three different genes (Tab. I).
In patient p1 the NGS revealed a novel missense variant c.14219G>T (p.(Gly4740Val)) and a known nonsense mutation c.7669C>T (p.Gln2557*) in the GPR98 gene ( Fig. 1a ., b.). The novel variant was predicted to be probably damaging by in silico analyses (Tab. I). Patient p2 is a compound heterozygous for a previously reported nonsense mutation c.5392C>T (p.Gln1798*) and a novel frameshift insertion c.5206_5207insC (p.(Lys1737Glnfs*28)) in the MYO7A gene ( Fig. 1c., d.) .
In patient p3 a novel variant c.11780A>G (p.(Asp3927Gly)) and one known mutation c.775_776delAG (p.Ser259Phefs*63) in the USH2A gene (in a heterozygous status) were identified ( Fig. 1e ., f.). In silico analysis of the missense substitution p.(Asp3927Gly) by PolyPhen2 and Mutation Taster 2 software showed that this variant is predicted to have a deleterious effect on usherin protein, while analysis by SIFT software indicated that this substitution is tolerated. PhyloP and GERP ++ score showed that nucleotide positions of the novel missense substitutions identified in patients p1 and p3 are evolutionarily conserved (Tab. I). None of the novel variants identified in this study was listed in the used databases. Furthermore, these variants were not detected in 100 control individuals from our in-house database.
Two known variants c.2299delG (p.Glu767Serfs*21) in USH2A and c.12704A>G (p.Tyr4235Cys) in the GPR98 gene were identified in patient p4. In two patients (p5 and p7), a known heterozygous variant in the USH2A gene was detected: c.11864G>A (p.Trp3955*), while the second allele remained undetermined. Finally, patient p6 had two different known mutations, c.9676C>T (p.Arg3226*) and c.9424G>T (p.Gly3142*), in the USH2A gene. All detected variants in USH patients are summarized in table I. Segregation analysis of novel variants performed in their healthy parents revealed that they segregate with the phenotype according to the autosomal recessive mode of inheritance (Fig. 1) .
Discussion
Here we report the results of targeted NGS of seven Polish patients with USH1 and USH2. Genetic background of the disease was identified in 71.4% patients with USH, which is consistent with the findings of other studies using the NGS method (14, 15 
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Next-generation sequencing reveals three novel variants in Polish patients with Usher syndrome the clinical classification of the patients, USH2 with variants detected in the USH2A and GPR98 genes and USH1 with a variant in the MYO7A gene. Despite a small sample size, we observed that the most frequent sequence variants in USH2 patients were identified in the USH2A gene (7 out of 9 variants in USH2). The results are consistent with the previous studies indicating that mutations in this gene are the most common cause of USH2 (16, 17) . Two mutated alleles were identified in five out of seven patients. We detected three novel variants c.14219G>T in the GPR98 gene, c.11780A>G in the USH2A gene and c.5206_5207insC in the MY-O7A gene. A novel missense variant c.14219G>T (p.(Gly4740Val)) in exon 70 of the GPR98 gene (p1) changes glycine to valine, both nonpolar amino acids, at amino acid residue 4740 that is highly conserved among species. Frameshift variant detected in one patient (p2), c.5206_5207insC (p.(Lys1737Glnfs*28)), located in exon 38, leading to a stop codon 28 amino acid downstream, causes premature termination of translation. A novel missense variant c.11780A>G identified in exon 61 of the USH2A gene (p3) (p.(Asp3927Gly)) is located in the fibronectin type 3 domain, which is involved in cell adhesion, its morphology, migration, thrombosis and embryonic differentiation. In one patient (p4), we identified heterozygous known variants in two different genes GPR98 and USH2A. A pathogenic frameshift variant c.2299delG in USH2A has been previously reported in USH patients. A missense substitution c.12704A>G in the GPR98 gene is a very rare variant (allele frequency based on ExAC is 0.0001968), which was predicted to be probably damaging by in silico analyses. The GERP score of 4.45 indicated that nucleotide position 12704 of the identified change p.Tyr4235Cys was likely damaging. The Grantham score of 194 means that Tyrosine and Cysteine are evolutionarily very distant from each other. Therefore, their substitution is predicted to be more damaging. The two detected trans-heterozygous variants are present in two genes, on two different chromosomes. Both genes are known to cause USH2. In view of all these results, the two detected variants may be considered pathogenic in this patient. Digenic inheritance in ciliopathies like Usher syndrome and Nephronophthisis has been reported previously (4, 18, 19) . Digenic inheritance of CDH23 and PCDH15 has been shown to cause Usher syndrome type I in humans (20) . As the presence of two additional variants in yet undiscovered USH genes, intragenic deletion or duplication cannot be excluded in the patient in question, further studies, especially in animal models, are required in order to confirm our assumptions of digenic inheritance in our patient. Many studies suggest that copy number variants can be significant USH2A mutations type that are missed by sequencing assays (14, 21, 22) . In the molecular analysis performed by Austin-Tse et al. in a group of 700 patients with hearing loss, copy number variants were identified in a significant proportion of the USH patients with a previously detected heterozygous variant only (23) .
In our cohort, we were unable to detect the second putative mutation in two patients, who were positive only for heterozygous mutations. This can most likely be explained by technical limitations of targeted sequencing. The panel sequencing is designed to target the coding sequence and exon-intron borders. For deep- ND -no data, CME -cystoid macular edema. RP -retinitis pigmentosa. Balance problems -normal balance, + abnormal balance. Novel mutations identified in this study are indicated in bold. They are given in parentheses because the consequences of these mutations are only predicted, not proven by functional experiments. Classification of novel variants according to American College of Medical Genetics and Genomics (ACMG) guidelines./ND -brak danych, CME -torbielowaty obrzęk plamki. RP -zwyrodnienie barwnikowe siatkówki. -prawidłowa równowaga, + problemy z równowagą,. Nowe mutacje zidentyfikowane w pracy zostały pogrubione. Nowe mutacje umieszczono w nawiasach, ponieważ konsekwencje mutacji przewidziano jedynie w programach predykcyjnych, nie zostały one natomiast eksperymentalnie udowodnione. Klasyfikację nowych wariantów wykonano na podstawie wytycznych American College of Medical Genetics and Genomics (ACMG).
Tab. I. Identified sequence variants and clinical information of USH patients. Tab. I. Informacje kliniczne oraz warianty sekwencji zidentyfikowane u pacjentów chorujących na zespół Ushera.
Next-generation sequencing reveals three novel variants in Polish patients with Usher syndrome -intronic and intragenic deletions or duplications, only such methods as whole genome sequencing (WGS) or array CGH could be effective. Additional whole exome sequencing (WES) could be a good alternative in order to identify mutations in known or novel genes which are not included in the USH panel.
The effective method which enables a reliable molecular diagnosis of USH can improve genetic counseling contributing to earlier diagnosis in children, as well as pre-symptomatic USH2 and USH3 patients, which can be crucial for preventive or treatment modalities, which are being developed. Novel variants identified in this study expand the spectrum of mutations in USH related genes, thereby enhancing the current knowledge of USH heterogeneity, and further support the use of targeted NGS in genetic diagnosis of Usher syndrome.
